Agilent Technologies, Inc. (A) Stock Analysis
Latest ClaritX AI analysis ·
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spect
| Metric | Value |
|---|---|
| Price | $167.77 |
| Market cap | $47.4B |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| ClaritX AI score | 80/100 |
| Price/Book | 6.43 |
| Dividend yield | 0.60% |
| Beta | 1.24 |
AI verdict
Agilent Technologies (NYSE: A) remains a flawlessly engineered, hyper-efficient compounder operating as the indispensable infrastructure backbone of the global life sciences industry. Fortified by an elite 20.47% Return on Equity, massive 53.73% gross margins, and a highly conservative 0.536 debt-to-equity ratio, the fundamental business is practically bulletproof. Management's recent aggressive cadence of product commercialization—including the NovoStation sample prep system, Gen5 AI integration, and TapeStationDx—was brilliantly front-run by massive corporate insider accumulation during the first half of the year, establishing an impregnable floor of high-conviction institutional support. However, from a strict tactical risk-management perspective, deploying fresh capital at these levels requires extreme caution. Trading at $167.77, the equity sits just 5.24% below its euphoric 52-week high of $177.05, accompanied by a technically overbought RSI of 74.96. Crucially, the asset possesses an elevated beta of 1.241, dictating that it mathematically amplifies broader market volatility. Acquiring a high-beta enterprise operating near its peak amidst explicit DCF valuation warnings of a $120 intrinsic floor carries immense multiple contraction risk. The underlying monopolistic business is virtually flawless, but the current technical price action strongly demands strict algorithmic patience. Rating 80/100
What this score has been worth
ClaritX scores A 80 out of 100 (snapshot 2026-10-05).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 189 analyses that scored in the 80-84 band, the average forward return was -1.2% with a 41% win rate, -6.3pp against the S&P 500. That is a measured tendency across many names, not a forecast for A — roughly 59% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.